Ann Arbor staging and Kaplan–Meier survival analysis demonstrated that elevated APOC1 expression is strongly associated with advanced clinical stages and decreased five-year overall survival in DLBCL patients, suggesting it as a prognostic indicator. This evidence concerns the gene APOC1 and diffuse large B-cell lymphoma.